Cell Death & Diff:肥胖治疗新靶点

2016-07-13 佚名 生物谷

肥胖是一类容易引发多种代谢紊乱疾病(如糖尿病心血管疾病以及脂肪肝等)的慢性疾病。前脂肪细胞(preadipocyte)向脂肪细胞(adipocyte)的转变,即脂肪生成过程,是青少年以及成年人发福的主要原因。在成年人体内,脂肪生成与脂肪细胞的凋亡两者之间的动态平衡使得体重维持在正常水平,尽管如此,人的身体中每年将有10%的脂肪细胞发生替换。因此,脂肪生成过程是肥胖防治的有效靶点。脂肪的生成依赖多步

肥胖是一类容易引发多种代谢紊乱疾病(如糖尿病心血管疾病以及脂肪肝等)的慢性疾病。前脂肪细胞(preadipocyte)向脂肪细胞(adipocyte)的转变,即脂肪生成过程,是青少年以及成年人发福的主要原因。在成年人体内,脂肪生成与脂肪细胞的凋亡两者之间的动态平衡使得体重维持在正常水平,尽管如此,人的身体中每年将有10%的脂肪细胞发生替换。因此,脂肪生成过程是肥胖防治的有效靶点。

脂肪的生成依赖多步骤的基因调控,其中核受体具有重要的作用。PPARγ表达于脂肪生成过程的中后期,对于脂肪细胞的分化与成熟具有正面的调控作用。NEDD8是一类类泛素蛋白,它常用于胞内蛋白的翻译后修饰,而与泛素化降解不同,NEDD8的修饰具有许多不同的作用,其中包括转录调控。由于实验证明肥胖小鼠中NEDD8的表达量会有明显提高,这一现象说明NEDD8对于脂肪生成过程也许具有一定的影响。
 
针对这一问题,来自韩国首尔国立大学医学院的Y-S Chun课题组进行了深入研究,相关结果发表在最近一期的《Cell Death & Differentiation》杂志上。
 
首先,作者利用3T3-L1细胞系进行脂肪生成的体外诱导试验,通过下调NEDD8的表达量,作者发现细胞脂肪化的进程受到了明显的抑制。之后,作者将野生型与NEDD8下调的前脂肪组织移植入小鼠体内,并观察其发育情况。结果显示,NEDD8的缺失能够抑制前脂肪细胞向脂肪细胞的转化。
 
进一步,作者发现NEDD8能够抑制PPARγ的泛素化,而这一过程有助于PPARγ活性的稳定。而这一过程依赖于E3泛素连接酶MDM2的参与。
 
最后,作者利用人工合成的化合物MLN4924处理细胞,发现这一处理能够抑制NEDD8对PPARγ的修饰并抑制脂肪生成的过程。体内试验也表明,使用MLN4924后小老鼠受到诱导的肥胖发生受到了一定程度的影响。
 
综上,作者利用一系列体内外试验证明了NEDD8是脂肪细胞生成过程的关键元件,这一蛋白可以作为治疗肥胖症的潜在药物靶点。

原始出处

H-S Park, U-I Ju, J-W Park, JY Song1 , DH Shin , K-H Lee , LS Jeong , J Yu , HW Lee, JY Cho, SY Kim, SW Kim, JB Kim, KS Park and Y-S Chun.PPARγ neddylation essential for adipogenesis is a potential target for treating obesity.Cell Death & Diff.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959720, encodeId=927d1959e20c8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 20 18:37:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869462, encodeId=86ef186946255, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Feb 09 08:37:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288172, encodeId=407f12881e275, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jul 15 08:37:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517354, encodeId=7206151e3546b, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Fri Jul 15 08:37:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531397, encodeId=1cbf153139e17, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Jul 15 08:37:00 CST 2016, time=2016-07-15, status=1, ipAttribution=)]
    2017-05-20 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959720, encodeId=927d1959e20c8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 20 18:37:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869462, encodeId=86ef186946255, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Feb 09 08:37:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288172, encodeId=407f12881e275, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jul 15 08:37:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517354, encodeId=7206151e3546b, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Fri Jul 15 08:37:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531397, encodeId=1cbf153139e17, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Jul 15 08:37:00 CST 2016, time=2016-07-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959720, encodeId=927d1959e20c8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 20 18:37:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869462, encodeId=86ef186946255, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Feb 09 08:37:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288172, encodeId=407f12881e275, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jul 15 08:37:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517354, encodeId=7206151e3546b, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Fri Jul 15 08:37:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531397, encodeId=1cbf153139e17, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Jul 15 08:37:00 CST 2016, time=2016-07-15, status=1, ipAttribution=)]
    2016-07-15 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1959720, encodeId=927d1959e20c8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 20 18:37:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869462, encodeId=86ef186946255, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Feb 09 08:37:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288172, encodeId=407f12881e275, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jul 15 08:37:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517354, encodeId=7206151e3546b, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Fri Jul 15 08:37:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531397, encodeId=1cbf153139e17, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Jul 15 08:37:00 CST 2016, time=2016-07-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1959720, encodeId=927d1959e20c8, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat May 20 18:37:00 CST 2017, time=2017-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869462, encodeId=86ef186946255, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Feb 09 08:37:00 CST 2017, time=2017-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288172, encodeId=407f12881e275, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Jul 15 08:37:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517354, encodeId=7206151e3546b, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Fri Jul 15 08:37:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531397, encodeId=1cbf153139e17, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Fri Jul 15 08:37:00 CST 2016, time=2016-07-15, status=1, ipAttribution=)]
    2016-07-15 cy0328

相关资讯

Diabet Med:无论有没有GDM,超重/肥胖都会增加剖宫产、子痫前期和大于胎龄儿的风险

肥胖的妊娠期糖尿病孕妇与正常体重高的非妊娠糖尿病孕妇相比,剖宫产、先兆子痫和大于胎龄儿的风险更大,不过近期的研究也表明,不管孕妇有没有妊娠糖尿病,超重和肥胖增加以上提到的风险。瑞典Örebro大学医学与健康科学学院的Karin Hilden博士和同事分析了1249908例孕妇BMI至少18.5 kg/m²的单胎妊娠情况,1型或2型糖尿病的女性被排除在外。获取了母亲的人口数据、孕期并发症,以及分娩和

FCVB 2016:减肥手术能逆转肥胖相关衰老

已有研究表明,肥胖与过早老化有关,支持这一过程的机制也正在慢慢地被发现。新的研究发现,减肥手术不仅有助于减肥,还能逆转分子老化。肥胖增加了一些严重疾病的风险,尤其是糖尿病和心血管疾病。临床上的肥胖还会加速衰老的过程,事实上,在过去的几年中,通过研究已经渐渐缩小了可疑分子过程的范围。早期的研究表明,肥胖增加脂肪细胞中的活性氧(自由基)水平,导致端粒的缩短,而这恰好是老化的一个标志。端粒是位于每个染色

《肥胖相关性高血压管理的中国专家共识》发布

近20年来,全球范围内肥胖和高血压的患病率均呈显著上升趋势,二者常合并存在。肥胖既可增加高血压患者血压控制的难度,也可促进多重心血管代谢危险因素的聚集,从而加重心脑血管损害。鉴于肥胖相关性高血压患病率高,危害性大,其评估与防治有特殊性,并受到国内外的关注,中华医学会心血管病学分会高血压学组综合国内外肥胖相关性高血压的研究成果,撰写了本专家共识,以促进肥胖相关性高血压的防治。诊断 肥胖与高血压常合并

多喝水可预防体重增加?无稽之谈

民众普遍认为,每天要喝足够的水才对机体健康有益。若机体不能获取足够的水,则机体的许多代谢活动如呼吸、流汗、排尿和排便都不能正常进行。水对机体正常运作十分重要,缺水会导致机体脱水、疲劳,严重者可危及生命。人们对水的需要量取决于体重、年龄和机体活动水平,一般建议成人饮水量为2.7——3.7升。 密歇根大学的新研究表明,BMI更高的民众不建议过多饮水。研究结果发表在the Annals of Famil

J Clin Res Pediatr Endocrinol:肥胖的儿童、青少年的TSH水平更高

近期有研究表明,肥胖的儿童和青少年与超重或正常体重的同类人群相比,可能有更高水平的促甲状腺激素(TSH)。这些差异的出现,可能是因为肥胖人群的甲状腺自身免疫性疾病的发病率较高所致。阿尔梅里亚Torrecárdenas医院的Emilio García-García博士和同事评估了1317名儿童和青少年(平均年龄8.8岁;女性占48.8%;38.4%的处于青春期),以探究不同体重状态下甲状腺功能和自身

Science:母亲孕期饮食会影响后代DNA的表达

英国伦敦大学玛丽皇后学院进行的而研究表明,母亲在怀孕期间的饮食可能会永久性地影响孩子的属性,它可以解释如2型糖尿病和肥胖等疾病是遗传的。这项研究发现,属性,如重量,可以通过一个意想不到的区域的基因组的遗传变异而形成。到目前为止,基因研究已经无法完全解释某些疾病包括2型糖尿病和肥胖的遗传过程。 发表在Science上的研究结果表明,核糖体DNA(rDNA)的遗传变异可以指导子宫内环境决定后代的属性。